This report was first published by Endpoints News. To see the original version, click here
Odyssey Therapeutics pulled together $279 million from its initial public offering, the autoimmune disease drug developer said Thursday night.
With its IPO now priced, Odyssey is slated to begin trading on the Nasdaq on Friday. The biotech sold 15.5 million shares $ODTX at $18 apiece, an upsized offer at the top of the range it marketed to investors. Separately, it sold another $25 million in shares at the same price in a private offering to TPG Life Sciences Innovations, it said, bringing its total raised to $304 million.
您已阅读43%（617字），剩余57%（815字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。